Isatuximab, carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed, transplantation-eligible multiple myeloma (SKylaRk): a single-arm, phase 2 trial

来那度胺 Carfilzomib公司 多发性骨髓瘤 地塞米松 医学 肿瘤科 移植 内科学
作者
Elizabeth O’Donnell,Clifton C. Mo,Andrew J. Yee,Omar Nadeem,Jacob P. Laubach,Jacalyn Rosenblatt,Nikhil C. Munshi,Shonali Midha,Diana Cirstea,Pavlina Chrysafi,Nora Horick,Paul G. Richardson,Noopur Raje
出处
期刊:The Lancet Haematology [Elsevier BV]
卷期号:11 (6): e415-e424 被引量:6
标识
DOI:10.1016/s2352-3026(24)00070-x
摘要

Summary

Background

Isatuximab is a CD38 monoclonal antibody approved for relapsed or refractory multiple myeloma. We aimed to evaluate the addition of isatuximab to weekly carfilzomib (K), lenalidomide (R), and dexamethasone (d; Isa-KRd) in transplant-eligible patients with newly diagnosed multiple myeloma and stratified maintenance by cytogenetic risk.

Methods

This single-arm phase 2 trial was done at three cancer centres (two hospitals and a cancer institute) in Boston (MA, USA). Eligible patients were aged at least 18 years and had transplant-eligible newly diagnosed multiple myeloma and an ECOG performance status of 2 or less. Patients received four 28-day cycles of Isa-KRd, including isatuximab 10 mg/kg intravenously weekly for 8 weeks, then every other week for 16 weeks, and every 4 weeks thereafter; carfilzomib 56 mg/m2 intravenously on days 1, 8, and 15 (20 mg/m2 for cycle 1 day 1); lenalidomide 25 mg orally on days 1–21; and dexamethasone 20 mg orally the day of and day after all doses of carfilzomib and isatuximab. Consolidation involved either upfront haematopoietic stem-cell transplantation (HSCT) with two additional cycles or deferred HSCT with four additional cycles of treatment. The primary endpoint was complete response after four cycles of treatment. Analyses were by intention-to-treat. All patients who received one dose of study drug were included in the safety analyses. This study was registered at ClinicalTrials.gov, NCT04430894, and has completed enrolment.

Findings

Between July 31, 2020 and Jan 31, 2022, 50 patients were enrolled. Median age was 59 years (range 40–70), 54% (27 of 50 patients) were male, and 44 (88%) were White. 46% (23 of 50) of patients had high-risk cytogenetics. Median follow-up was 26 months (IQR 20·7–30·1). 32% (16 of 50 patients) achieved a complete response after four cycles. The overall response rate (ORR) was 90% (45 patients) and 78% (39 patients) achieved a very good partial response (VGPR) or better. After completion of consolidation, 58% (29 patients) achieved a complete response; the ORR was 90% (45 patients) and 86% (43 patients) achieved a VGPR or better. The most common grade 3 or 4 side-effects (≥two patients) included neutropenia (13 [26%] of 50 patients), elevated alanine aminotransferase (six [12%] patients), fatigue (three [6%] patients), thrombocytopenia (three [6%] patients), acute kidney injury (two [4%] patients), anaemia (two [4%] patients), and febrile neutropenia (two [4%] patients). Grade 1–2 infusion-related reactions were seen in 20% (ten patients), with none grade 3. Grade 1–2 hypertension was seen in 14% (seven patients) with one grade 3 (one [2%] patient). There were two deaths assessed as unrelated to treatment.

Interpretation

Although the study did not achieve the prespecified complete response threshold, Isa-KRd induced deep and durable responses in transplant-eligible patients with newly diagnosed multiple myeloma. The treatment proved safe and consistent with similar regimens in this setting.

Funding

Amgen, Sanofi, and Adaptive.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
haoran_man发布了新的文献求助10
3秒前
4秒前
朴素的寒荷完成签到,获得积分20
5秒前
橘子味的北冰洋完成签到 ,获得积分10
5秒前
传奇3应助lvsehx采纳,获得10
5秒前
6秒前
www完成签到,获得积分10
6秒前
8秒前
香蕉觅云应助yanziwu94采纳,获得10
8秒前
Survivor完成签到,获得积分10
9秒前
张蓓蓓发布了新的文献求助10
9秒前
Zxffei完成签到,获得积分10
10秒前
10秒前
15秒前
停停走走发布了新的文献求助10
17秒前
老金金完成签到 ,获得积分10
19秒前
yanziwu94发布了新的文献求助10
20秒前
20秒前
haoran_man完成签到,获得积分20
20秒前
CipherSage应助停停走走采纳,获得10
23秒前
sci完成签到,获得积分10
24秒前
25秒前
25秒前
木冉完成签到 ,获得积分10
25秒前
外向的沛柔关注了科研通微信公众号
27秒前
停停走走完成签到,获得积分20
29秒前
小二郎应助1111采纳,获得20
32秒前
叶子完成签到,获得积分10
32秒前
赵银志发布了新的文献求助10
32秒前
38秒前
母单花完成签到 ,获得积分10
41秒前
木穹完成签到,获得积分10
44秒前
归雁发布了新的文献求助10
46秒前
青基立项完成签到 ,获得积分10
46秒前
orixero应助阿俊1212采纳,获得10
48秒前
hadfunsix完成签到 ,获得积分10
49秒前
科研通AI5应助飘逸妙柏采纳,获得10
50秒前
1111完成签到 ,获得积分20
50秒前
慕青应助枫叶采纳,获得10
51秒前
阡陌完成签到,获得积分10
53秒前
高分求助中
【此为提示信息,请勿应助】请按要求发布求助,避免被关 20000
Production Logging: Theoretical and Interpretive Elements 3000
CRC Handbook of Chemistry and Physics 104th edition 1000
Izeltabart tapatansine - AdisInsight 600
Introduction to Comparative Public Administration Administrative Systems and Reforms in Europe, Third Edition 3rd edition 500
Distinct Aggregation Behaviors and Rheological Responses of Two Terminally Functionalized Polyisoprenes with Different Quadruple Hydrogen Bonding Motifs 450
Individualized positive end-expiratory pressure in laparoscopic surgery: a randomized controlled trial 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 物理 生物化学 纳米技术 计算机科学 化学工程 内科学 复合材料 物理化学 电极 遗传学 量子力学 基因 冶金 催化作用
热门帖子
关注 科研通微信公众号,转发送积分 3761774
求助须知:如何正确求助?哪些是违规求助? 3305540
关于积分的说明 10134658
捐赠科研通 3019564
什么是DOI,文献DOI怎么找? 1658226
邀请新用户注册赠送积分活动 791989
科研通“疑难数据库(出版商)”最低求助积分说明 754751